X4 Pharmaceuticals (XFOR) Stock Analysis & AI Equity Report
X4 Pharmaceuticals (XFOR) overview
X4 Pharmaceuticals (XFOR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 35.1m and operating profit of USD -86.9m; the year-end share price was 4.00 USD and market capitalisation was USD 364m. X4 Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get X4 Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About X4 Pharmaceuticals
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing therapeutics for rare hematology diseases. Its commercially approved product, XOLREMDI (mavorixafor), is an oral therapy for patients aged 12 and older with WHIM syndrome. The company is also studying mavorixafor in chronic neutropenia, including congenital, acquired primary autoimmune and idiopathic forms.
Generate the X4 Pharmaceuticals report
X4 Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for X4 Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on X4 Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.